文献速递糖尿病

膜联蛋白A1通过恢复Akt信号减轻1型糖尿病小鼠模型的微血管并发症

Annexin A1 attenuates microvascular complications through restoration of Akt signalling in a murine model of type 1 diabetes.
PubMed 文献 · Diabetologia · 2017-10-30

研究检测1型糖尿病患者血浆膜联蛋白A1(ANXA1)水平,并在链脲佐菌素诱导的1型糖尿病小鼠中探讨内源性ANXA1的作用及人重组ANXA1的治疗效果。结果显示糖尿病患者ANXA1升高,ANXA1缺失加重心肾功能障碍,人重组ANXA1可减轻或阻止心肾功能的进一步下降,并恢复Akt磷酸化。

要点

  • 1型糖尿病伴或不伴肾病患者血浆ANXA1水平均高于健康人。
  • ANXA1缺失的糖尿病小鼠心脏射血分数更低、蛋白尿更重。
  • 人重组ANXA1预防性或治疗性给药可减轻或阻止糖尿病小鼠心肾功能恶化。

核心结论

  • 1型糖尿病患者血浆ANXA1水平升高,且不依赖于肾功能显著受损。
  • 在链脲佐菌素诱导的1型糖尿病小鼠中,ANXA1通过使MAPK信号回归基线并激活促生存通路Akt,保护心脏和肾脏功能。
  • 作者提出ANXA1可能是控制1型糖尿病共病的潜在治疗选择。

研究设计与样本

  • 研究采用床旁到实验台的方法,检测1型糖尿病伴或不伴肾病患者及健康供者血浆ANXA1水平。
  • 在C57BL/6或Anxa1基因敲除小鼠中,通过连续5天每日静脉注射链脲佐菌素(45 mg/kg)诱导实验性1型糖尿病。
  • 糖尿病小鼠接受人重组ANXA1(1 μg,100 μl,50 mmol/l HEPES;140 mmol/l NaCl;pH 7.4,腹腔注射)或溶剂(100 μl,50 mmol/l HEPES;140 mmol/l NaCl;pH 7.4,腹腔注射)治疗。

主要发现

  • 1型糖尿病伴肾病和不伴肾病患者血浆ANXA1分别为66.0 ± 4.2 ng/ml和64.0 ± 4 ng/ml,均高于健康人的35.9 ± 2.3 ng/ml(p < 0.05)。
  • 与糖尿病野生型小鼠相比,糖尿病Anxa1基因敲除小鼠心脏射血分数为49.9 ± 0.9% vs 76.1 ± 1.6%,蛋白尿为113.3 ± 5.5 μg/mg vs 89.3 ± 5.0 μg/mg,表型更差。
  • 与非糖尿病野生型小鼠相比,非糖尿病Anxa1基因敲除小鼠心脏和肾脏中p38、JNK和ERK的磷酸化程度显著更高,链脲佐菌素诱导1型糖尿病后进一步增强。
  • 预防性给予人重组ANXA1(第1-13周)使糖尿病小鼠射血分数为72.4 ± 1.0% vs 54.0 ± 1.6%,蛋白尿为53.1 ± 3.4 μg/mg vs 89.3 ± 5.0 μg/mg,减轻心肾功能障碍。
  • 在心脏和肾脏功能障碍已显著发展后治疗性给予人重组ANXA1(第8-13周),阻止了糖尿病小鼠心肾功能进一步下降;人重组ANXA1还减轻p38、JNK和ERK磷酸化增加并恢复Akt磷酸化。

临床怎么用

  • 作者提出ANXA1可能是控制1型糖尿病共病的潜在治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Microvascular complications in the heart and kidney are strongly associated with an overall rise in inflammation. Annexin A1 (ANXA1) is an endogenous anti-inflammatory molecule that limits and resolves inflammation. In this study, we have used a bedside to bench approach to investigate: (1) ANXA1 levels in individuals with type 1 diabetes; (2) the role of endogenous ANXA1 in nephropathy and cardiomyopathy in experimental type 1 diabetes; and (3) whether treatment with human recombinant ANXA1 attenuates nephropathy and cardiomyopathy in a murine model of type 1 diabetes. METHODS: ANXA1 was measured in plasma from individuals with type 1 diabetes with or without nephropathy and healthy donors. Experimental type 1 diabetes was induced in mice by injection of streptozotocin (STZ; 45 mg/kg i.v. per day for 5 consecutive days) in C57BL/6 or Anxa1 -/- mice. Diabetic mice were treated with human recombinant (hr)ANXA1 (1 μg, 100 μl, 50 mmol/l HEPES; 140 mmol/l NaCl; pH 7.4, i.p.) or vehicle (100 μl, 50 mmol/l HEPES; 140 mmol/l NaCl; pH 7.4, i.p.). RESULTS: Plasma levels of ANXA1 were elevated in individuals with type 1 diabetes with/without nephropathy compared with healthy individuals (66.0 ± 4.2/64.0 ± 4 ng/ml vs 35.9 ± 2.3 ng/ml; p < 0.05). Compared with diabetic wild-type (WT) mice, diabetic Anxa1 -/- mice exhibited a worse diabetic phenotype and developed more severe cardiac (ejection fraction; 76.1 ± 1.6% vs 49.9 ± 0.9%) and renal dysfunction (proteinuria; 89.3 ± 5.0 μg/mg vs 113.3 ± 5.5 μg/mg). Mechanistically, compared with non-diabetic WT mice, the degree of the phosphorylation of mitogen-activated protein kinases (MAPKs) p38, c-Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) was significantly higher in non-diabetic Anxa1 -/- mice in both the heart and kidney, and was further enhanced after STZ-induced type 1 diabetes. Prophylactic treatment with hrANXA1 (weeks 1-13) attenuated both cardiac (ejection fraction; 54.0 ± 1.6% vs 72.4 ± 1.0%) and renal (proteinuria; 89.3 ± 5.0 μg/mg vs 53.1 ± 3.4 μg/mg) dysfunction associated with STZ-induced diabetes, while therapeutic administration of hrANXA1 (weeks 8-13), after significant cardiac and renal dysfunction had already developed, halted the further functional decline in cardiac and renal function seen in diabetic mice administered vehicle. In addition, administration of hrANXA1 attenuated the increase in phosphorylation of p38, JNK and ERK, and restored phosphorylation of Akt in diabetic mice. CONCLUSIONS/INTERPRETATION: Overall, these results demonstrate that ANXA1 plasma levels are elevated in individuals with type 1 diabetes independent of a significant impairment in renal function. Furthermore, in mouse models with STZ-induced type 1 diabetes, ANXA1 protects against cardiac and renal dysfunction by returning MAPK signalling to baseline and activating pro-survival pathways (Akt). We propose ANXA1 to be a potential therapeutic option for the control of comorbidities in type 1 diabetes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Purvis GSD, Chiazza F, Chen J, et al. Annexin A1 attenuates microvascular complications through restoration of Akt signalling in a murine model of type 1 diabetes. Diabetologia. 2017. PMID: 29085990. doi:10.1007/s00125-017-4469-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。